Mortality after admission for heart failure in the UK compared with Japan

Toshiyuki Nagai,1,2,3 Varun Sundaram,1,2,4,5 Kieran Rothnie,1 Jennifer Kathleen Quint,1 Ahmad Shoaib,6 Yasuyuki Shiraishi,7 Shun Kohsaka,7 Susan Piper,9 Theresa A McDonagh,8 Suzanna Marie C Hardman,9 Ayumi Goda,10 Atsushi Mizuno,11 Takashi Kohn,7 Alan S Rigby,12 Tsutomu Yoshikawa,13 Andrew L Clark,14 Toshihisa Anzai,2,3 John G F Cleland14,15

ABSTRACT

Objective Mortality amongst patients hospitalised for heart failure (HFH) in Western and Asian countries may differ, but this has not been investigated using individual patient-level data (IPLD). We sought to remedy this through rigorous statistical analysis of HFH registries and variable selection from a systematic literature review.

Methods and results IPLD from registries of HFH in Japan (n=3781) and the UK (n=894) were obtained. A systematic literature review identified 23 models for predicting outcome of HFH. Five variables appearing in 10 or more reports were strongly related to prognosis (systolic blood pressure, serum sodium concentration, age, blood urea nitrogen and creatinine). To compare mortality in the UK and Japan, variables were imputed in a propensity model using inverse probability of treatment weighting (IPTW) and IPTW with logistic regression (doubly robust IPTW). Overall, patients in the UK were sicker and in-patient and post-discharge mortalities were greater, suggesting that the threshold for hospital admission was higher. Covariate-adjusted in-hospital mortality was similar in the UK and Japan (IPTW OR: 1.14, 95% CI 0.70 to 1.86), but 180-day postdischarge mortality was substantially higher in the UK (doubly robust IPTW OR: 2.33, 95% CI 1.58 to 3.43).

Conclusions Despite robust methods to adjust for differences in patient characteristics and disease severity, HFH patients in the UK have roughly twice the mortality at 180 days compared with those in Japan. Similar analyses should be done using other data sets and in other countries to determine the consistency of these findings and identify factors that might inform healthcare policy and improve outcomes.

INTRODUCTION

Annually, heart failure (HF) accounts for >80,000 admissions in the UK1 >200,000 in Japan2 3 and >1 million in the USA. Among patients hospitalised for heart failure (HFH), in-hospital mortality is reported to vary from 2.0% to 12.0% 3–10 and mortality at 1-year postdischarge from 13.3% to 30.5%. 1,6 11

Differences in mortality estimates for HFH might be due to variations in patient characteristics, severity of HF, comorbidities or medical care. Substantial international differences in health service provision may also exist, including criteria for admission, length of stay, care in the community after discharge and treatment. There will also be cultural differences in both the art of medicine and patient attitudes to medical advice, especially between Western and Asian countries. To date, outcomes for HFH in different healthcare systems have been investigated only using aggregate rather than individual patient-level data (IPLD). Comparing the characteristics and outcomes of HFH managed in different cultures might identify differences in practice that could improve care.
Accordingly, we investigated in-hospital and post-discharge mortality using IPLD from registries of HHF in the UK and Japan, adjusting for differences in key prognostic variables identified from a systematic review of published mortality prediction models (MPMs) and using inverse probability of treatment weighting (IPTW) techniques.

**METHODS**

**Overall study design**

Our main objective was to compare the mortality of HHF patients in the UK and Japan after adjusting for differences in baseline covariates. This involved three steps: (1) first, a systematic review of published MPMs for HHF, identifying the variables predicting mortality and estimating their respective predictive weights; (2) subsequently, the predictors identified by the review were imputed in a propensity model using IPTW to identify patients with similar attributes in the UK and Japan; and (3) finally, outcomes of interest between the weighted groups, including in-hospital, 30-day, 90-day and 180-day post-discharge mortality, were evaluated.

**Systematic review**

We searched the Medline/PubMed and Embase databases to identify relevant MPMs. We employed search filters that have been validated and shown to have high sensitivity for identification of clinical prediction models in Medline12 (online supplementary appendix) to Supplementary file 1 identify 4487 MPMs for HHF. Those with models only for composite outcomes (ie, HF hospitalisation and mortality), those published only as abstracts and duplicate reports were excluded. We also excluded studies when model performance was not quantified using c-statistics or receiver operating characteristic curves. This identified 23 unique MPMs from which information on individual predictor variables could be extracted. For the meta-analyses, studies lacking OR or HR for predictor variables were excluded; 17 studies were finally included in the meta-analysis (figure 1). All studies were reviewed by two independent cardiologists (TN and VS) to ascertain eligibility (see online supplementary table for details on data extraction and reduction, and statistical analysis).

**Study cohorts**

Pooled data from two UK and two Japanese registries of HHF were used. In all registries, HHF was defined by hospitalisation with a diagnosis of HF according to the Framingham criteria.

**UK HHF cohort**

1. The Hull and East Yorkshire Hospitals NHS Trust, King’s College Hospital NHS Foundation Trust (London) and Whittington Hospital NHS Trust (London) are three large tertiary care hospitals that each provides emergency care to approximately 500,000 people. All three Trusts participate in the England and Wales National Heart Failure Audit. From 2012 to 2013, 697 HHF patients (307 from Hull; 390 from London) were enrolled. Because it is a National Health Service (NHS) registry, neither specific ethical review nor patient consent is required.

2. The Hull LifeLab is a large, epidemiologically representative, information-rich data set of contemporary diagnosis, treatment and natural history of patients with HF. Its main focus is on out-patient referrals; only patients hospitalised for HF at the time of enrolment between 2010 and 2011 (n=197) were included in this analysis. The registry has ethical approval and patients gave written informed consent.

**Japanese HHF cohort**

1. The WET-HF (WEst Tokyo Heart Failure) registry is an ongoing, prospective observational registry of HHF in five large academic medical centres in metropolitan Tokyo that enrolled 3030 patients between 2005 and 2016.14

2. The NaDEF (National cerebral and cardiovascular center for acute DEcompensated heart Failure) registry enrolled 751 patients between 2013 and 2015 from a large centre for cardiovascular medicine located in mid-west Japan.15

The study protocols were registered at the Japanese University hospital Medical Information Network (UMIN) Clinical Trial Registration (UMIN000001171 and UMIN000017024, respectively).

**Statistical analysis**

The weights of variables predicting mortality were meta-analysed, using fixed-effect and random-effect models. The z-scores (OR/SE and HR/SE) of the OR (for case–control studies) and the HR (for cohort studies) of predictor variables were estimated.16 Continuous variables were presented as mean±SD. Baseline variables that were significantly different between the two groups were identified using standardised differences. Among these variables, those that were used in more than one MPM (n≥2) and available in both countries were imputed in an IPTW model to develop balanced groups.17 Balance between the British and Japanese weighted cohorts was evaluated using the standardised differences approach and kernel density plots. For propensity analyses, IPTW was preferred over matching in order to preserve the sample size.18

We performed univariable/multivariable logistic regression analyses, IPTW and IPTW with logistic regression (doubly robust IPTW) to compare odds for mortality (in-hospital, 30-day postdischarge, 90-day post-discharge and 180-day postdischarge) in the UK and Japanese cohorts. Additional analysis was performed for postdischarge mortality after controlling for medicines at discharge. All analyses were performed with Stata MP64 V.15.
RESULTS

Systematic review of MPMs

We identified 28 different MPMs from 23 papers published between 2003 and 2017 (online supplementary table). The five variables with the top z-scores were systolic blood pressure (BP), serum sodium concentration, age, blood urea nitrogen (BUN) and serum creatinine; 26 predictor variables appeared in more than one MPM (table 1).

Cohort baseline characteristics

The baseline characteristics of patients in the UK (n=894) and Japan (n=3781) are shown in table 2. The mean age was similar in UK and Japan, but British patients had more severe HF as evidenced by higher New York Heart Association (NYHA) class, lower systolic BP, lower serum sodium concentrations, higher BUN and serum creatinine concentrations. A higher proportion of Japanese patients had a left ventricular ejection fraction >45%. The prevalence of ischaemic heart disease and chronic pulmonary obstructive disease (COPD)/asthma was higher among British patients compared with their Japanese counterparts.

Inverse probability of treatment weighting

After application of IPTW with variables which were used in two or more MPMs and available in both countries (systolic BP, hyponatraemia, age, serum creatinine, COPD/asthma, heart rate, NYHA class, ischaemic heart disease, stroke, left ventricular ejection fraction, atrial fibrillation, diabetes mellitus and sex), there was good balance between British and Japanese patients’ characteristics. Standardised differences were <0.1 for most variables other than haemoglobin and medications at discharge. After additional weighting for oral medications at discharge (ACE inhibitor/angiotensin II receptor

Figure 1. Flow diagram of the meta-analyses of published mortality prediction models in HHF patients. AUC, area under the curve; HHF, hospitalised due to heart failure.
blocker, beta blocker, mineralocorticoid receptor antagonist, diuretics and digitalis), balance (standardised difference <0.1) was achieved for all key variables (table 2).

Mortality before and after IPTW in the UK compared with Japan
Crude analyses showed that mortality was substantially higher in the UK compared with Japan at all time-points (table 3). Unadjusted mortality during hospitalisation was 3.6% in the UK vs 2.2% in Japan, and was, respectively, 3.5% vs 2.7% at 30 days, 9.0% vs 4.4% at 90 days, and 14.7% vs 6.3% at 180 days. Multivariable logistic regression analyses in the unweighted population showed that in-hospital mortality was similar in the UK and Japan, but British patients had a substantially higher mortality by 180 days (table 3). Weighted and doubly robust weighted analyses also showed higher mortality in the UK at 180 days. Because of the low number of events, we did not have the statistical power to perform doubly robust weighted analyses for in-hospital, 30-day (with and without accounting for medications at discharge) and 90-day mortality (after accounting for medications at discharge) (table 3).

**DISCUSSION**
This analysis suggests that HHF patients in the UK have more advanced disease than their Japanese counterparts and a much worse prognosis. After adjusting for differences in patient characterististics using IPTW, in-hospital mortality was similar in the UK and Japan, suggesting that the quality of in-patient care might be similar. However, substantial differences in post-discharge mortality persisted even after adjusting for the prognostic variables that were identified by a systematic literature review and available in both countries. As far as we know, this is the first analysis comparing HHF in Western and Asian

| Variables                        | n   | OR  | z-Score | Mean  | 95% CI | HR  | z-Score | Mean  | 95% CI |
|----------------------------------|-----|-----|---------|-------|--------|-----|---------|-------|--------|
| Systolic blood pressure          | 21  | 42.62 | 1.17    | 1.11 to 1.23 | 51.40 | 1.18 | 1.13 to 1.22 |
| Serum sodium                     | 21  | 43.27 | 1.15    | 1.09 to 1.20 | 17.40 | 1.20 | 1.06 to 1.33 |
| Age                              | 21  | 21.09 | 1.41    | 1.28 to 1.54 | 14.08 | 1.39 | 1.19 to 1.58 |
| Blood urea nitrogen              | 16  | 27.44 | 1.57    | 1.46 to 1.68 | 39.86 | 1.29 | 1.22 to 1.35 |
| Creatinine                       | 14  | 12.73 | 1.33    | 1.12 to 1.53 | 9.29  | 1.43 | 1.13 to 1.73 |
| COPD/asthma                      | 8   | 10.00 | 1.53    | 1.23 to 1.82 | 12.86 | 1.44 | 1.22 to 1.66 |
| Heart rate                       | 7   | 45.24 | 1.18    | 1.13 to 1.23 | –     | –    | –       |
| Albumin                          | 6   | 34.73 | 1.57    | 1.48 to 1.66 | 11.26 | 1.42 | 1.17 to 1.66 |
| Haemoglobin                      | 6   | 15.11 | 1.30    | 1.13 to 1.47 | –     | –    | –       |
| Cancer                           | 6   | 7.75  | 2.45    | 1.83 to 3.07 | –     | –    | –       |
| NYHA class                       | 6   | 4.57  | 2.26    | 1.29 to 3.03 | –     | –    | –       |
| Ischaemic heart disease          | 4   | –     | –       | –       | 23.95 | 1.21 | 1.11 to 1.30 |
| Dementia                         | 4   | 20.05 | 1.85    | 1.67 to 2.03 | –     | –    | –       |
| Stroke                           | 4   | 10.31 | 1.38    | 1.12 to 1.64 | –     | –    | –       |
| Oxygen saturation                | 4   | 2.02  | 2.05    | 0.07 to 4.03 | –     | –    | –       |
| Respiratory rate                 | 3   | 34.59 | 1.18    | 1.11 to 1.24 | –     | –    | –       |
| Sex                              | 3   | 30.59 | 1.29    | 1.20 to 1.37 | –     | –    | –       |
| LVEF                             | 3   | 9.62  | 1.15    | 0.91 to 1.38 | –     | –    | –       |
| (N-terminal pro) BNP             | 3   | 7.05  | 1.85    | 1.33 to 2.36 | –     | –    | –       |
| Transfer by EMS                  | 3   | 5.74  | 3.81    | 2.51 to 5.11 | –     | –    | –       |
| Liver cirrhosis                  | 3   | 2.20  | 4.01    | 0.44 to 7.58 | –     | –    | –       |
| Prior heart failure hospitalisation | 3   | –     | –       | –       | –     | –    | –       |
| Potassium                        | 3   | –     | –       | –       | –     | –    | –       |
| Troponin                         | 3   | –     | –       | –       | –     | –    | –       |
| Atrial fibrillation              | 3   | –     | –       | –       | –     | –    | –       |
| Diabetes mellitus                | 2   | –     | –       | –       | –     | –    | –       |

BNP, brain natriuretic peptide; COPD, chronic pulmonary obstructive disease; EMS, emergency medical service; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
| Variable                        | % Missing UK/Japan | Unweighted study population | Weighted study population unadjusted for medicines at discharge | Weighted study population adjusted for medicines at discharge |
|--------------------------------|-------------------|----------------------------|---------------------------------------------------------------|------------------------------------------------------------|
|                                |                   | UK          | Japan          | Standardised difference | UK          | Japan          | Standardised difference | UK          | Japan          | Standardised difference |
| Patients, n                   | –                 | 894         | 3781           | –                     | 681         | 1814           | –                             | 605         | 1373           | –                             |
| Age, years                    | 0.1/0             | 73.5 (13.7) | 74.5 (13.1)    | −0.073                | 72.5 (14.0) | 72.4 (13.9)    | 0.002                          | 71.7 (14.4) | 72.3 (13.7)    | −0.040                          |
| Male sex, n (%)               | 0/5.7             | 555 (62)    | 2147 (60)      | 0.038                 | 66%         | 64%            | 0.029                          | 65%         | 65%            | 0.003                          |
| NYHA III or IV, n (%)         | 2.7/27.2          | 802 (92)    | 2259 (82)      | 0.037                 | 91%         | 91%            | −0.007                          | 91%         | 91%            | 0.020                          |
| Systolic BP, mm Hg            | 0.6/12.8          | 132 (29)    | 139 (33)       | −0.226                | 134 (29)    | 133 (31)       | 0.018                          | 134 (30)    | 134 (31)       | −0.022                          |
| Heart rate, bpm               | 0.7/13.3          | 91.1 (27.4) | 93.6 (29.2)    | −0.089                | 93.2 (27.5) | 92.3 (27.6)    | 0.030                          | 91.6 (27.3) | 91.8 (27.0)    | −0.008                          |
| LVEF ≤45%, n (%)              | 12.6/18.1         | 560 (72)    | 1763 (57)      | 0.312                 | 75%         | 73%            | 0.030                          | 72%         | 72%            | 0.008                          |
| Comorbidities, n (%)          |                   |             |                |                       |             |                |                                |             |                |                                |
| IHD                            | 0/0               | 433 (48)    | 961 (25)       | 0.491                 | 40%         | 41%            | −0.008                          | 40%         | 43%            | −0.050                          |
| Diabetes mellitus             | 0.1/0.1           | 297 (33)    | 1394 (37)      | −0.076                | 32%         | 33%            | −0.016                          | 31%         | 32%            | −0.029                          |
| Hypertension                  | 0.1/0.5           | 512 (57)    | 2664 (71)      | −0.204                | 56%         | 63%            | −0.139                          | 57%         | 63%            | −0.127                          |
| COPD/asthma                   | 0/15.6            | 221 (25)    | 169 (5)        | 0.565                 | 12%         | 12%            | −0.006                          | 14%         | 14%            | 0.006                           |
| Atrial fibrillation           | 0.6/15.4          | 374 (41)    | 1550 (48)      | −0.129                | 41%         | 41%            | −0.005                          | 41%         | 40%            | 0.026                           |
| Stroke                        | 1.3/15.6          | 88 (10)     | 532 (17)       | −0.198                | 12%         | 11%            | 0.035                           | 10%         | 10%            | 0.013                           |
| Laboratory data               |                   |             |                |                       |             |                |                                |             |                |                                |
| Haemoglobin, g/dL             | 43.7/0.4          | 12.2 (2.1)  | 11.9 (2.3)     | 0.142                 | 12.4 (2.1)  | 12.2 (2.3)     | 0.133                          | 12.3 (2.1)  | 12.2 (2.3)     | 0.059                           |
| Sodium, n (%)                 | 0.1/0.5           | 137.1 (6.8) | 139.2 (5.4)    | −0.333                | –           | –              | –                              | –           | –              | –                              |
| Hyponatraemia, n (%)          | 0.1/0.5           | 264 (30)    | 558 (15)       | 0.360                 | 23%         | 22%            | 0.018                          | 22%         | 22%            | 0.003                           |
| BUN, mg/dL                    | 41.7/0.7          | 32.1 (24.2) | 27.7 (17.9)    | 0.206                 | 28.4 (21.5) | 28.3 (18.0)    | 0.052                          | 28.1 (19.8) | 27.9 (19.6)    | 0.006                           |
| Creatinine, mg/dL             | 0.5/0.5           | 1.54 (1.24) | 1.50 (1.57)    | 0.028                 | 1.48 (1.07) | 1.49 (1.49)    | −0.010                         | 1.45 (1.06) | 1.50 (1.61)    | −0.029                          |
| Oral medications at discharge, n (%) |             |             |                |                       |             |                |                                |             |                |                                |
| ACE-I/ARBs                     | 28.1/1.9          | 682 (76)    | 2331 (62)      | 0.465                 | 81%         | 64%            | 0.493                          | 84%         | 82%            | 0.061                           |
| Beta blockers                 | 8.1/1.9           | 640 (72)    | 2698 (71)      | 0.118                 | 80%         | 77%            | 0.071                          | 80%         | 79%            | 0.021                           |
| MRA                           | 22.5/6.9          | 126 (14)    | 585 (15)       | 0.352                 | 52%         | 38%            | 0.287                          | 47%         | 48%            | −0.008                          |
| Diuretics                     | 6.4/6.5           | 748 (84)    | 2487 (66)      | 0.492                 | 91%         | 76%            | 0.415                          | 90%         | 90%            | 0.012                           |
| Digitalis                    | 24.5/6.4          | 105 (12)    | 325 (9)        | 0.427                 | 26%         | 9%             | 0.463                          | 18%         | 18%            | 0.003                           |
| Length of hospitalisation, days | 0.0/8.7          | 14.9 (13.3) | 21.9 (32.3)    | −0.284                | 15.0 (13.8) | 24.1 (37.3)    | −0.324                         | 14.4 (12.7) | 24.1 (33.4)    | −0.386                          |

Continuous variables are presented as mean (SD). Categorical variables are presented as number of patients (%).

A standardised difference of 0.1 denotes meaningful imbalance in the variables.

ACE-I, ACE inhibitor; ARB, angiotensin II receptor blocker; BP, blood pressure; bpm, beats per minute; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; IHD, ischaemic heart disease; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.
The fact that different methods of adjustment provided similar results suggests that our study has considerable internal validity. Globally, HHF patients are common, and the numbers are expected to rise as the proportion of older people in the population increases and survival with conditions such as hypertension, ischaemic heart disease and HF itself improves.2 19–21 Internationally, guidelines on the management of HF are rather similar but less is known about the differences among patients from different cultures to whom the guidelines are applied. For example, HHF patients in Japan are reported to have a longer length of hospital stay (Japan: 15–21 days; Europe: 7–9 days; USA: 4 days) and lower in-hospital mortality (Japan: 2.0%–5.6%; Europe: 5.5%–6.7%; USA: 3.8%–8.9%).4–7 10 22–24 However, these are crude estimates unadjusted for differences in disease severity. We identified 26 prognostic variables for HHF in a systematic review and used these to adjust for variations in patient characteristics that might have accounted for the differences in mortality. To our knowledge, this is the first systematic review of prognostic variables for HHF; previous systematic reviews focused on chronic HF.16 Despite risk adjustment, 180-day postdischarge mortality remained substantially higher in the UK than in Japan.

Differences in post-discharge mortality could reflect many factors, including genetics, age, environment, diet, lifestyle, and other unmeasured confounders. We believe the difference is largely due to differences in post-discharge care. In Japan, patients are seen in the outpatient clinic within 4 weeks of discharge, even for patients who are not specified for follow-up. The Japanese diet includes more rice and less wheat; more salt; more fish and less red meat.25 The weather is warmer in Tokyo than in England. In Japan, patients are less likely to follow medical advice and adhere to their prescribed medications. While our analysis estimates the differences in outcomes after adjusting for identified predictor variables, it was not designed to identify the reason for residual disparities.

The limitations of this study are as follows: while both the UK and Japan registries had detailed IPLD, certain important variables that were identified from a systematic literature review, such as respiratory rate, serum albumin, troponin, brain natriuretic peptide levels, and medication compliance were not consistently available. This study is geographically limited to patients hospitalised in Britain and Japan; our results may not generalise to other Western or Asian countries. Finally, the study was not designed to identify the reason for residual disparities. However, we believe these are the main limitations of our study.

| Table 3 | Outcomes for British and Japanese HHF patients using multiple adjustment techniques |
|---------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|         | UK vs Japan                      | Crude                           | Crude                           | Unweighted                      | Unweighted                      | Weighted                        | Weighted                        |
|         |                                 | OR (95% CI)                     | P values                        | OR (95% CI)                     | P values                        | OR (95% CI)                     | P values                        |
| In-hospital | 1.83 (1.28 to 2.63)             | 0.001                           | 1.10 (0.68 to 1.80)             | 0.69                           | 1.14 (0.70 to 1.86)             | 0.59                           | –                              |
|         | Unadjusted for medications at discharge |                                    |                                  |                                |                                |                                |                                |
| 30-day postdischarge | 2.32 (1.60 to 3.37)              | <0.001                          | 1.96 (1.18 to 3.24)             | 0.009                          | 1.92 (1.14 to 3.24)             | 0.014                          | –                              |
| 90-day postdischarge | 2.52 (1.97 to 3.23)              | <0.001                          | 1.79 (1.28 to 2.51)             | 0.001                          | 1.88 (1.33 to 2.64)             | <0.001                         | 1.92 (1.34 to 2.75)             | <0.001                        |
| 180-day postdischarge | 2.57 (2.09 to 3.17)              | <0.001                          | 1.96 (1.49 to 2.60)             | <0.001                         | 2.12 (1.59 to 2.81)             | <0.001                         | 2.21 (1.63 to 2.99)             | <0.001                        |
|        | Adjusted for medications at discharge |                                    |                                  |                                |                                |                                |                                |
| 30-day postdischarge | 2.32 (1.60 to 3.37)              | <0.001                          | 2.71 (1.23 to 5.94)             | 0.013                          | 2.55 (0.97 to 6.74)             | 0.059                          | –                              |
| 90-day postdischarge | 2.52 (1.97 to 3.23)              | <0.001                          | 2.45 (1.59 to 3.79)             | <0.001                         | 2.32 (1.46 to 3.68)             | <0.001                         | –                              |
| 180-day postdischarge | 2.57 (2.09 to 3.17)              | <0.001                          | 2.55 (1.83 to 3.55)             | <0.001                         | 2.25 (1.58 to 3.22)             | <0.001                         | 2.33 (1.58 to 3.43)             | <0.001                        |

HHF, hospitalised for heart failure; IPLD, itemised patient-level data; IPTW, inverse probability of treatment weighting.
that these limitations are outweighed by methodological strengths, including prospective patient enrolment from multiple centres, a systematic review to identify predictor variables and their estimated weights, and the use of multiple adjustment methods including conventional covariate adjustment, IPTW and doubly robust IPTW, all of which yielded similar results.

CONCLUSION
HHF patients in the UK have a substantially worse prognosis compared with those hospitalised in Japan. Differences persist after accounting for the greater severity of patients admitted with HF in the UK. Explaining the differences in outcome among countries, cultures and health services might provide insights that could improve care and outcome and inform healthcare policy decisions.

Author affiliations
1National Heart & Lung Institute, Imperial College London, London, UK
2Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan
3Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan
4Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA
5Royal Brompton and Harefield Hospitals, London, UK
6Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, University of Keele and Royal Stoke Hospital, Stoke-on-Trent, UK
7Department of Cardiology, Keio University School of Medicine, Tokyo, Japan
8Cardiology Department, King’s College Hospital, London, UK
9Clinical and Academic Department of Cardiovascular Medicine, Whittington Hospital, London, UK
10Division of Cardiology, Kyorin University School of Medicine, Tokyo, Japan
11Department of Cardiology, St Luke’s International Hospital, Tokyo, Japan
12Department of Statistics, Hull York Medical School, University of Hull, Kingston-upon-Hull, UK
13Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan
14Department of Cardiology, Hull York Medical School, Castle Hill Hospital, Kingston-upon-Hull, UK
15Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow and National Heart & Lung Institute, Royal Brompton & Harefield Hospitals, Imperial College London, London, UK

Funding TN is supported by grants from the Daiichi Sankyo Foundation of Life Science and the Mochida Memorial Foundation for Medical and Pharmaceutical Research. This research was supported by a Butterfield Award for UK–Japan collaboration in Medicine and Health from The Great Britain Sasakawa Foundation.

Competing interests JGFC received grants and honoraria from Amgen, Novartis, Medtronic, Philips, Servier and Stealth BioTherapeutics.

Patient consent Obtained.

Ethics approval The study protocols of both the Japanese registries were approved by the respective institutional review boards.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES
1. Cleland JG, McDonagh T, Rigby AS, et al. The national heart failure audit for England and Wales 2008–2009. Heart 2011;97:876–86.
2. Okura Y, Ramadani MM, Ohno Y, et al. Impending epidemic: future projection of heart failure in Japan to the year 2065. Circ J 2008;72:489–91.
3. Yasuda S, Nakao K, Nishimura K, et al. The Current Status of Cardiovascular Medicine in Japan6– Analysis of a Large Number of Hospital Records From a Nationwide Claim-Based Database, JROAD-DPC. Circ J 2016;80:3237–35.
4. Honda S, Nagai T, Sugano Y, et al. Prevalence, determinants, and prognostic significance of delirium in patients with acute heart failure. Int J Cardiol 2016;222:521–7.
5. Fonorow GC, Adams KA, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005;293:572–80.
6. Chioncel O, Mebazaa A, Harjola VP, et al. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1242–54.
7. Abraham WT, Fonorow GC, Albert NM, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 2008;52:347–56.
8. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003;290:2581–7.
9. Lee SE, Cho HJ, Lee HY, et al. A multicentre cohort study of acute heart failure syndromes in Korea: rationale, design, and interim observations of the Korean Acute Heart Failure (KoA HF) registry. Eur J Heart Fail 2014;16:700–8.
10. Sato N, Kajimoto K, Asai K, et al. Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. Am Heart J 2010;159:949–55.
11. Park JJ, Choi DJ, Yoon CH, et al. Prognostic value of C-reactive protein as an inflammatory and N-terminal probrain natriuretic peptide as a neurohumoral marker in acute heart failure (from the Korean Heart Failure Registry). Am J Cardiol 2014;113:511–7.
12. Geersing GJ, Bouwmeester W, Zuitthof P, et al. Search filters for finding prognostic and diagnostic prediction studies in Medline to enhance systematic reviews. PLoS One 2012;7:e32844.
13. Cleland JG, Zhang J, Pellicori P, et al. Prevalence and Outcomes of Anemia and Hematocrit Deficiencies in Patients With Chronic Heart Failure. JAMA Cardiol 2016;1:539–47.
14. Takei M, Kohsaka S, Shiraishi Y, et al. Effect of estimated plasma volume reduction on renal function for acute heart failure differs between patients with preserved and reduced ejection fraction. Circ Heart Fail 2015;8:327–32.
15. Nagai T, Nishimura K, Homma T, et al. Prognostic significance of endogenous erythropoietin in long-term outcome of patients with acute decompensated heart failure. Eur J Heart Fail 2016;18:803–13.
16. Owuerkerk W, Voors AA, Zwierman AH, Factors influencing the predictive power of models for predicting mortality and/or heart failure hospitalization in patients with heart failure. JACC Heart Fail 2014;2:429–36.
17. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res 2011;46:399–424.
18. Elze MC, Gregson J, Baber U, et al. Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies. J Am Coll Cardiol 2017;69:345–57.
19. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004;292:344–50.
20. Levy D, Krenchia S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397–402.
21. He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med 2005;353:1124–34.
22. Komajda M, Hanon O, Hochadel M, et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J 2009;30:478–86.
23. Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, et al. Characteristics, management, and outcomes for patients during hospitalization due to worsening heart failure–A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). J Cardiol 2013;62:95–101.
24. Makino J, Kohsaka S, Shiraishi Y, et al. Application of the United States acute heart failure risk prediction model in Japanese patients; analysis from a contemporary multicenter registry. Int J Cardiol 2015;195:323–5.
25. Stamler J, Brown IJ, Daviglus ML, et al. Dietary glycine and blood pressure: the International Study on Macro/Micronutrients and Blood Pressure. *Am J Clin Nutr* 2013;98:136–45.

26. Arimura T, Miura S, Morito N, et al. Recent Patient Characteristics and Medications at Admission and Discharge in Hospitalized Patients With Heart Failure. *J Clin Med Res* 2016;8:97–104.

27. Hori M, Sasayama S, Kitabatake A, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. *Am Heart J* 2004;147:324–30.

28. Dierckx R, Cleland JG, Parsons S, et al. Prescribing patterns to optimize heart rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period. *JACC Heart Fail* 2015;3:224–30.